Aldeyra Therapeutics

About:

Aldeyra Therapeutics develops next-generation medicines to improve the lives of patients with immune-mediated diseases.

Website: http://www.aldeyra.com/

Twitter/X: aldeyraaldx

Top Investors: Hercules Capital

Description:

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Total Funding Amount:

$287M

Headquarters Location:

Burlington, Massachusetts, United States

Founded Date:

2004-01-01

Contact Email:

lroth(AT)theruthgroup.com

Founders:

John E. Dowling, Thomas A. Jordan

Number of Employees:

11-50

Last Funding Date:

2021-04-28

IPO Status:

Public

Industries:

© 2025 bioDAO.ai